Cytotoxicity News and Research

RSS

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

In a recent study by researchers in Mexico, Russia and Spain, silver nanoparticles (AgNPs) were found to inhibit SARS-CoV-2 in healthcare workers. They propose a non-pharmaceutical public health intervention consisting of mouthwash and nose rinse with an AgNPs solution to reduce morbidity among healthcare personnel exposed to the SARS-CoV-2 virus.

24 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Phosphatidic acid is a key common substrate for hepatitis C and SARS-CoV-2 replication

A new study, released as a preprint on the bioRxiv* server, focuses on the lipid molecule called phosphatidic acid (PA), showing its crucial role in the replication of this virus, and thus its potential as a target for therapeutic intervention.

13 May 2021

Study: Repeated vape aerosol exposure causes minimal lung damage compared to combustible cigarettes

In one of the most advanced applications of in-vitro 3D human lung models in vape research to date, a new peer-reviewed Imperial Brands study shows that, unlike combustible cigarette smoke, blu aerosol had little to no impact on numerous toxicological endpoints under the conditions of test using laboratory models.

6 May 2021

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Drawing on epidemiological field studies and the FrenchCOVID hospital cohort coordinated by Inserm, teams from the Institut Pasteur, the CNRS and the Vaccine Research Institute (VRI, Inserm/University Paris-Est Créteil) studied the antibodies induced in individuals with asymptomatic or symptomatic SARS-CoV-2 infection.

21 Apr 2021

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

During the process of SARS-CoV-2 infection, once the virus penetrates the host cell, two open reading frames, ORF1a and ORF1ab, are translated. ORF1ab is responsible for the production of 16 nonstructural proteins (nsp). Several viral proteases such as 3CLpro and PLpro (papain-like protease) produce 1-16 nsps. A new study has been published in bioRxiv* preprint server, which deals with identifying drugs that are effective as PLpro inhibitors.

13 Apr 2021

Inhibition of nsp14 methyltransferase as a potential antiviral target for SARS-CoV-2

Beyond vaccination, the broad-spectrum antiviral medication remdesivir has robust clinical evidence and is known as the best antiviral treatment to reduce severe COVID-19 infection in hospitalized patients. Research led by John F.X. Diffley of the Chromosome Replication Laboratory suggests a potential therapeutic target for treatment development is the viral RNA cap methyltransferases, essential for viral protein translation and immune evasion.

13 Apr 2021

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

Upon SARS-CoV-2 infection, what are the changes occurring on the surface of the host cell? To address this, and a team of researchers undertook a study exploring the natural killer (NK) cells and their role during a SARS-CoV-2 infection.

12 Apr 2021

Screening for SARS-CoV-2 non-structural protein 14 inhibitors

In a paper recently uploaded to the preprint server bioRxiv* by Diffley et al. (April 8th, 2021), inhibitors of one essential SARS-CoV-2 non-structural protein are explored, with four compounds, in particular, identified as potential antiviral leads that exhibit synergistic effects with antiviral drug remdesivir.

12 Apr 2021

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

A team of scientists from the USA and Sweden has recently screened 8 million small molecule inhibitors against SARS-CoV-2.

5 Apr 2021

Study paves way for effective monitoring of chemotherapeutic drug level in cancer patients

Cancer is the world's second deadliest disease which contributes towards the fatality of over 10 million people per year.

3 Apr 2021

Developing orally administrable drugs to combat SARS-CoV-2

Researchers in China have reported the successful design and synthesis of two antiviral compounds that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)’s main protease, essential in virus replication.

29 Mar 2021

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.

24 Mar 2021

Researchers develop innovative biosensor that can detect and quantitate SARS-CoV-2 infection

Researchers have generated protease-activatable fluorescent and luminescent biosensors for SARS-CoV-2 MPro (main protease) and PLPro (papain-like protease) activity, one based on “flip” GFP (FlipGFP), and the other based on circularly permuted firefly luciferase (FFluc).

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Cytotoxicity News and Research

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Phosphatidic acid is a key common substrate for hepatitis C and SARS-CoV-2 replication

Study: Repeated vape aerosol exposure causes minimal lung damage compared to combustible cigarettes

Stem cell therapy for COVID-19 and ARDS

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

SARS-CoV-2 infection induces polyfunctional antibodies that can destroy infected cells

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

Inhibition of nsp14 methyltransferase as a potential antiviral target for SARS-CoV-2

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

Screening for SARS-CoV-2 non-structural protein 14 inhibitors

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers Identify potent small molecule inhibitors against SARS-CoV-2

Study paves way for effective monitoring of chemotherapeutic drug level in cancer patients

Developing orally administrable drugs to combat SARS-CoV-2

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Researchers develop innovative biosensor that can detect and quantitate SARS-CoV-2 infection

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News